DURHAM, NC--(Marketwire - October 21, 2010) - Aldagen, Inc. today announced that Edward L. Field, Executive Vice President and Chief Operating Officer of Aldagen, has been appointed Vice Chairman of the Alliance for Regenerative Medicine (ARM). ARM is an advocacy organization that represents the interests of the regenerative medicine community. Aldagen was one of the charter members of the organization when it was founded in 2009.
"I am honored to be part of an organization that has the potential to truly change the future of regenerative medicine," said Edward L. Field, EVP and COO of Aldagen. "The regenerative medicine field has tremendous potential, but faces many unique challenges, and I am thankful that we now have a strong political voice to represent and help further our efforts. Since ARM was founded last year the group has grown to include many of the major players in regenerative medicine and made tremendous progress, including the introduction of The Regenerative Medicine Promotion ACT of 2010 to the House of Representatives last month."
The Alliance for Regenerative Medicine is a Washington, DC-based non-profit organization whose mission is to educate key policy makers about the potential of regenerative medicine and to advocate for favorable public policies to facilitate advances in the field. Mr. Field also serves as Chair of ARM's Regulatory and Reimbursement Committee. This committee oversees development and implementation of the regulatory agenda for ARM.
"I have enjoyed working with Ed during the past year, and we are pleased to welcome him on board as Vice Chairman of ARM," said Morrie Ruffin, Managing Director of ARM. "Aldagen's technology holds great promise to develop new treatments that may dramatically improve or cure certain cardiovascular conditions. ARM has a lot to accomplish during the next year, and I know that Ed's commitment and experience will be of great value as we help move the regenerative medicine field forward."
Aldagen is a clinical-stage biopharmaceutical company developing proprietary regenerative cell therapies. Our product candidates consist of a specific population of a patient's own stem cells, which are isolated using our proprietary technology and which we believe have the potential to promote the regeneration of multiple types of cells and tissues, including the growth of new blood vessels. Our initial focus is on developing product candidates to address cardiovascular disease. Our cardiovascular product candidates are ALD-301 for the treatment of critical limb ischemia, ALD-201 for the treatment of ischemic heart failure, and ALD-401 for the post-acute treatment of ischemic stroke.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.